新股消息 | 迈威生物港股IPO招股书失效

智通财经
Jul 07, 2025

智通财经APP获悉,迈威(上海)生物科技股份有限公司-B(以下简称:迈威生物)(688062.SH)于2025年1月6日所递交的港股招股书满6个月,于2025年7月6日失效,递表时中信证券和海通国际为联席保荐人。

据招股书,迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。多年来,公司建立了具有竞争力的、多层次的管线产品组合,包括10个以上的药物资产且覆盖不同品种,专注于肿瘤和年龄相关疾病,如免疫、眼科、骨科等领域。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10